関連する実験動画
Updated: Dec 31, 2025

06:52
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
1.7K
ゲノム解析とエピジェネティック解析による新しい網膜母細胞腫治療法
Jinghui Zhang1, Claudia A Benavente, Justina McEvoy
1Department of Computational Biology and Bioinformatics, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Nature
|January 13, 2012
まとめ
幼児期の急速な網膜がんであるレチノブラストーマは,RB1遺伝子の喪失から生じる. 腫瘍は安定したゲノムを示しますが,SYKアップレギュレーションのようながん経路における表遺伝的変化は,急速な進行を促します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- レチノブラストーマは,RB1遺伝子のバイアレル性喪失によって引き起こされる,攻撃的な子供の網膜がんです.
- RB1不活性化後の急速な腫瘍の進行は,遺伝子変異を超えた基礎的なメカニズムを示唆しています.
研究 の 目的:
- RB1 喪失後の急速な網膜芽細胞腫の進行を促すメカニズムを調査する.
- レチノブラストーマ発症における協力的な遺伝的または表遺伝的イベントを特定する.
主な方法:
- 網膜芽細胞腫腫瘍の全ゲノム配列決定.
- ゲノム安定性におけるRB1の役割の評価.
- 癌経路における表皮遺伝的規制緩和の評価.
- SYK阻害のインビトロおよびインビボ試験.
主要な成果:
- 網膜芽細胞腫ゲノムは,低変異率で遺伝的に安定しています.
- RB1は,これまで知られている癌遺伝子の中で唯一一貫して変異した遺伝子でした.
- SYKアップレギュレーションを含むがん経路の表遺伝的緩和が観察されました.
- SYKを阻害剤で標的化すると,網膜芽細胞腫細胞死が誘発される.
結論:
- 網膜母細胞腫の進行は,遺伝的変異のみではなく,がん経路の表遺伝的緩和によって引き起こされます.
- RB1の喪失は,腫瘍の急速な成長を促す表遺伝的変化につながる可能性があります.
- SYKは,網膜芽細胞腫の潜在的な治療標的である.
関連する概念動画
The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K

